Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

Blood (2024) 144 (4): 392–401.

https://doi.org/10.1182/blood.2024023847

Published: 2024

Includes: Supplemental data

Journal Articles

Risk Factors for CD19-Targeting CAR T Manufacturing Failure and Patient Outcomes: A Report from the UK National CAR T Panel

Vaishali Dulobdas, Amy A Kirkwood, Fabio Serpenti, Brijesh Gautama, Aikaterini Panapoulou, Sumantha Gabriel, Ram Malladi, Jessica Pealing, Denise Bonney, Emma Nicholson, Caroline Besley, Sara Ghorashian, Elizabeth Davies, Jackie Chappell, Anne Black, Tobias Menne, Maeve O'Reilly, Robin Sanderson, Sridhar Chaganti

Blood (2023) 142 (Supplement 1): 495.

https://doi.org/10.1182/blood-2023-178834

Published: 2023

Journal Articles

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 222.

https://doi.org/10.1182/blood-2023-179454

Published: 2023

Journal Articles

The MEK Inhibitor Selumetinib in Combination with Dexamethasone Leads to Responses in Adult and Pediatric Patients with Relapsed RAS-Pathway Mutated Acute Lymphoblastic Leukemia: Results of a Phase 1/2 Study

Britta Julia Vormoor, Tobias Menne, Joshua Savage, Amit Patel, Anna Castleton, Adele Kay Fielding, Donna Lancaster, Anne Louise Latif, Nick Morley, Geoff Shenton, Gareth Veal, Julie Irving, Pam Kearns, Lucinda Billingham, Josef Vormoor

Blood (2023) 142 (Supplement 1): 2874.

https://doi.org/10.1182/blood-2023-185855

Published: 2023

Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-134398

Published: 2020

Journal Articles

Bendamustine Plus Rituximab for the Treatment of Waldenström Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-140774

Published: 2020

Journal Articles

Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 113.

https://doi.org/10.1182/blood-2019-123047

Published: 2019

Journal Articles

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Mehdi Hamadani, MD, Graham P. Collins, MB BS DPhil, Felipe Samaniego, MD, Alexander I Spira, MD, Andrew Davies, John Radford, MD FRCP, Paolo Caimi, MD, Tobias Menne, MD PhD, Joseph Boni, PhD, Hans Cruz, Jay Feingold, MD PhD, Shui He, PhD, Jens Wuerthner, Steven M. Horwitz, MD

Blood (2018) 132 (Supplement 1): 928.

https://doi.org/10.1182/blood-2018-99-118198

Published: 2018

Journal Articles

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Graham P. Collins, MB BS DPhil, Steven M. Horwitz, MD, Andrew Davies, Anand Karnad, MD, Felipe Samaniego, MD, Alexander I Spira, MD, Paul A Fields, MD PhD, Tobias Menne, MD PhD, Joseph Boni, PhD, Hans Cruz, Jay Feingold, MD PhD, Shui He, PhD, Jens Wuerthner, Mehdi Hamadani, MD

Blood (2018) 132 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2018-99-115986

Published: 2018

Journal Articles

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Steven M. Horwitz, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Jay Feingold, MD PhD, Alexander I Spira, MD, Paul A Fields, MD PhD, Tobias Menne, MD PhD, Anand Karnad, MD, Alison J. Moskowitz, MD, Catherine Hildyard, MRCP, BA, Shui He, PhD, Joseph Boni, PhD, Graham Collins, MD PhD

Blood (2017) 130 (Supplement 1): 1510.

https://doi.org/10.1182/blood.V130.Suppl_1.1510.1510

Published: 2017

Journal Articles

Evaluation Of IKZF1 Δ4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial

Nahid Zareian, Bella Patel, MBBS, FRCPath, Lena Rai-Shetty, PhD, Clare Rowntree, PhD, Andrew McMillan, FRCP, FRCPath, PhD, David I Marks, Tobias Menne, Paul Smith, Simon Purnell, Lynda Micklewright, Anthony V. Moorman, Adele Fielding, MB BS, PhD

Blood (2013) 122 (21): 1335.

https://doi.org/10.1182/blood.V122.21.1335.1335

Published: 2013

Journal Articles

Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14

Bella Patel, MB, BS, MD, A Kirkwood, Aditi Dey, Clare Rowntree, Andrew McMillan, FRCP, FRCPath, PhD, David Marks, MD, PhD, Tobias Menne, Paul Smith, PhD, Simon Purnell, Lynda Micklewright, Adele K Fielding, MB, BS, PhD

Blood (2013) 122 (21): 3900.

https://doi.org/10.1182/blood.V122.21.3900.3900

Published: 2013

Journal Articles

Haemophagocytic Lymphohistiocytosis Following Fludarabine/Cyclophosphamide Chemotherapy for Chronic Lymphocytic Leukaemia

Deepa Ranjani Jayakody Arachchillage, Samuel Moses, Stephen O'Brien, Tobias Menne, Peter Carey, Fiona Keenan, Jonathan Wallis

Blood (2011) 118 (21): 4617.

https://doi.org/10.1182/blood.V118.21.4617.4617

Published: 2011

NARROW

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

Risk Factors for CD19-Targeting CAR T Manufacturing Failure and Patient Outcomes: A Report from the UK National CAR T Panel

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

The MEK Inhibitor Selumetinib in Combination with Dexamethasone Leads to Responses in Adult and Pediatric Patients with Relapsed RAS-Pathway Mutated Acute Lymphoblastic Leukemia: Results of a Phase 1/2 Study

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Bendamustine Plus Rituximab for the Treatment of Waldenström Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing

Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Evaluation Of IKZF1 Δ4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial

Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14

Haemophagocytic Lymphohistiocytosis Following Fludarabine/Cyclophosphamide Chemotherapy for Chronic Lymphocytic Leukaemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only